Reported Saturday, Johnson & Johnson's Phase 2 DAHLIAS Study Reveals Nipocalimab Yields Over 70% Improvement in Sjögren's Disease Activity Compared To Placebo
Reported Saturday, Johnson & Johnson's Phase 2 DAHLIAS Study Reveals Nipocalimab Yields Over 70% Improvement in Sjögren's Disease Activity Compared To Placebo
據週六報道，約翰遜公司第二期DAHLIAS研究報告顯示Nipocalimab相較於安慰劑在Sjögren病活動方面提高了70%以上。
- Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo
- Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments
- 接受15mg/kg 的nipocalimab患者相對於接受安慰劑的患者，主要終點呈現了大於70%的相對平均改善。
- Sjögren's病是一種慢性、令人痛苦和流行的自身抗體性疾病，目前尚無批准的愛文思控股先進治療。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。